Ligand Announces Positive Preclinical Data on Small-Molecule G-CSF Receptor Agonist at ASH

Ligand Pharmaceuticals LGND announced that data from preclinical studies on its granulocyte colony stimulating factor (G-CSF) receptor agonist program were featured in a poster presentation today at the 55th Annual Meeting of the American Society of Hematology (ASH) in New Orleans. In preclinical studies, Ligand evaluated the ability of LGD-7455 to stimulate neutrophil (white blood cell) counts in cynomolgus monkeys and investigated the role that metal ions play in the activity of LGD-7455 on the G-CSF receptor (G-CSFR). Additionally, the effects and mechanisms of LGD-7455 on tumor cell growth were examined. The key findings include: See full press release
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsGuidanceFinancingContractsManagementGlobalBiotechnologyHealth Care
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!